Related Experiment Video
Updated: May 16, 2026
05:41
Synchronous Triplanar Reconstruction Integrated with Color Doppler Mapping for Precise and Rapid Localization of Thyroid Lesions
Published on: February 9, 2024
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid
Jason D Prescott1, Peter M Sadow, Richard A Hodin
1Endocrine Surgery Unit, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-2696, USA.
Surgery
|November 20, 2012
Summary
BRAF V600E mutation status improves papillary thyroid cancer recurrence prediction. Adding this genetic marker to existing risk algorithms enhances accuracy for patients undergoing total thyroidectomy.
Area of Science:
- Oncology
- Genetics
- Medical Diagnostics
Background:
- Papillary thyroid cancer (PTC) recurrence risk stratification remains challenging.
- Current risk classification systems do not integrate BRAF mutational status.
- Predicting PTC recurrence requires improved methodologies.
Purpose of the Study:
- To evaluate the incremental value of BRAF V600E mutational status in predicting PTC recurrence.
- To assess the impact of BRAF status on existing risk stratification algorithms.
Main Methods:
- Analysis of a historical cohort of 356 patients who underwent total thyroidectomy for PTC.
- BRAF V600E genotyping of archived tumor specimens.
- Cox proportional hazard regression modeling incorporating BRAF status into established algorithms (AMES, MACIS, AJCC-TNM, ATA).
Main Results:
- The 5-year cumulative PTC recurrence incidence was 15%.
- BRAF V600E mutation was present in 54% of genotyped specimens.
- BRAF V600E status significantly improved recurrence prediction across all tested algorithms (HR 2.43-2.51) and enhanced model discrimination (incremental c-index 0.046-0.109).
Conclusions:
- Incorporating BRAF V600E mutational status into risk algorithms significantly improves the prediction of recurrence in papillary thyroid cancer.
- This genetic marker offers valuable incremental prognostic information for patients with PTC.
Related Concept Videos
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...